Disease characteristics and clinical outcome over two decades from the Swiss pulmonary hypertension registry.
Paula AppenzellerMona LichtblauCharlotte BerlierJohn-David AubertAndrea AzzolaJean-Marc FellrathThomas GeiserFrederic LadorSusanne PohleIsabelle OpitzMarkus SchwerzmannHans StrickerMichael TammStéphanie SaxerStéphanie SaxerPublished in: Pulmonary circulation (2022)
Pulmonary hypertension (PH), especially pulmonary arterial and chronic thromboembolic pulmonary hypertension (PAH/CTEPH), are rare and progressive conditions. Despite recent advances in treatment and prognosis, PH is still associated with impaired quality of life and survival. Long-term PH-registry data provide information on the changing PH-epidemiology and may help to direct resources to patient's needs. This retrospective analysis of the Swiss Pulmonary Hypertension Registry includes patients newly diagnosed with PH (mainly PAH/CTEPH) registered from January 2001 to June 2019 at 13 Swiss hospitals. Patient characteristics (age, body mass index, gender, diagnosis), hemodynamics at baseline, treatment, days of follow-up, and events (death, transplantation, pulmonary endarterectomy, or loss to follow-up) at last visit were analyzed. Patients were stratified into four time periods according to their date of diagnosis. Survival was analyzed overall and separately for PAH/CTEPH and time periods. 1427 PH patients were included (thereof 560 PAH, 383 CTEPH). Over the years, age at baseline (mean ± SD) significantly increased from 59 ± 14 years in 2001-2005 to 66 ± 14 years in 2016-2019 ( p < 0.001) while the gender distribution tended toward equality. Mean pulmonary artery pressure and pulmonary vascular resistance significantly decreased over time (from 46 ± 15 to 41 ± 11 mmHg, respectively, 9 ± 5 to 7 ± 4 WU, p < 0.001). Three-year survival substantially increased over consecutive periods from 69% to 91% (for PAH 63%-95%, for CTEPH 86%-93%) and was poorer in PAH than CTEPH independently of time period ( p < 0.001). Most patients were treated with mono- or combination therapy and an increasing number of CTEPH underwent pulmonary endarterectomy (40% 2016-2019 vs. 15% 2001-2005). This long-term PH registry reveals that over two decades of observation, newly diagnosed patients are older, less predominantly female, have less impaired hemodynamics and a better survival.
Keyphrases
- pulmonary hypertension
- newly diagnosed
- pulmonary artery
- end stage renal disease
- ejection fraction
- chronic kidney disease
- body mass index
- combination therapy
- peritoneal dialysis
- pulmonary arterial hypertension
- prognostic factors
- healthcare
- coronary artery
- patient reported outcomes
- coronary artery disease
- bone marrow
- social media
- artificial intelligence
- atrial fibrillation
- electronic health record
- mesenchymal stem cells
- cross sectional
- health information
- acute coronary syndrome
- replacement therapy